Analysis18 May 2018 15:33
So the depth of his analysis is "Reneuron don't sell anything.....It's all well and good having potential, but unless they actually reach Phase III, get approval and bring something to market, with their cash burn, they're effed mate" - well of course that sets them apart from every single other pre-market stage biotech, doesn't it? We're all here on a punt, there's reasons to believe in Rene, and of course given the last 12 months, there's reasons to doubt. If all this chap has to contribute is - "but they are not making any money and they might not in future" - then he's really wasting a lot of his time.